Micheline Piquette-Miller

List of Publications by Year
in descending order

124 papers	5,264 citations	57758 44 h-index	91884 69 g-index
125 all docs	125 docs citations	125 times ranked	5741 citing authors

#	Article	IF	Citations
1	Inflammatory Cytokines, but Not Bile Acids, Regulate Expression of Murine Hepatic Anion Transporters in Endotoxemia. Journal of Pharmacology and Experimental Therapeutics, 2002, 303, 273-281.	2.5	197
2	The Involvement of the Pregnane X Receptor in Hepatic Gene Regulation during Inflammation in Mice. Journal of Pharmacology and Experimental Therapeutics, 2005, 312, 841-848.	2.5	159
3	Polymeric drug delivery systems for localized cancer chemotherapy. Drug Delivery, 2010, 17, 365-375.	5.7	158
4	REGULATION OF DRUG TRANSPORTERS: DURING INFECTION AND INFLAMMATION. Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics, 2007, 7, 99-111.	3.4	146
5	INDUCTION OF ABCC3 (MRP3) BY PREGNANE X RECEPTOR ACTIVATORS. Drug Metabolism and Disposition, 2003, 31, 1296-1299.	3.3	136
6	Regulation of the hepatic multidrug resistance gene expression by endotoxin and inflammatory cytokines in mice. International Immunopharmacology, 2001, 1, 189-199.	3.8	132
7	Decreased expression and activity of P-glycoprotein in rat liver during acute inflammation. Pharmaceutical Research, 1998, 15, 706-711.	3.5	121
8	Synthesis and Physicochemical and Dynamic Mechanical Properties of a Water-Soluble Chitosan Derivative as a Biomaterial. Biomacromolecules, 2006, 7, 2845-2855.	5.4	121
9	Downregulation of mdr1a expression in the brain and liver during CNS inflammation alters the in vivo disposition of digoxin. British Journal of Pharmacology, 2003, 139, 35-48.	5.4	111
10	Research Directions in the Clinical Implementation of Pharmacogenomics: An Overview of US Programs and Projects. Clinical Pharmacology and Therapeutics, 2018, 103, 778-786.	4.7	110
11	Hepatoprotective role of PXR activation and MRP3 in cholic acid-induced cholestasis. British Journal of Pharmacology, 2007, 151, 367-376.	5.4	109
12	Ethnic differences in drug metabolism and toxicity from chemotherapy. Expert Opinion on Drug Metabolism and Toxicology, 2009, 5, 243-257.	3.3	106
13	Cellular localization and functional expression of P-glycoprotein in rat astrocyte cultures. Journal of Neurochemistry, 2004, 89, 788-800.	3.9	97
14	Diseaseâ€Associated Changes in Drug Transporters May Impact the Pharmacokinetics and/or Toxicity of Drugs: A White Paper From the International Transporter Consortium. Clinical Pharmacology and Therapeutics, 2018, 104, 900-915.	4.7	91
15	Inflammation-mediated changes in drug transporter expression/activity: implications for therapeutic drug response. Expert Review of Clinical Pharmacology, 2012, 5, 69-89.	3.1	89
16	Decreased expression of P-glycoprotein in interleukin-1Î² and interleukin-6 treated rat hepatocytes. Inflammation Research, 2001, 50, 362-370.	4.0	85
17	Functional and molecular characteristics of Na(+)-dependent nucleoside transporters. Pharmaceutical Research, 1997, 14, 1524-1532.	3.5	82
18	Biocompatibility of injectable chitosanâ€“phospholipid implant systems. Biomaterials, 2009, 30, 3818-3824.	11.4	82

#	Article	IF	Citations
19	Regulation of Multidrug Resistance by Pro-Inflammatory Cytokines. Current Cancer Drug Targets, 2006, 6, 295-311.	1.6	79
20	Animal Models of Acute Moderate Hypoxia Are Associated with a Down-Regulation of CYP1A1, 1A2, 2B4, 2C5, and 2C16 and Up-Regulation of CYP3A6 and P-glycoprotein in Liver. Drug Metabolism and Disposition, 2007, 35, 765-771.	3.3	79
21	The Art and Science of Personalized Medicine. Clinical Pharmacology and Therapeutics, 2007, 81, 311-315.	4.7	79
22	Influence of IL-6 on MDR and MRP-mediated multidrug resistance in human hepatoma cells. Canadian Journal of Physiology and Pharmacology, 2001, 79, 876-884.	1.4	74
23	IMPACT OF ENDOTOXIN-INDUCED CHANGES IN P-GLYCOPROTEIN EXPRESSION ON DISPOSITION OF DOXORUBICIN IN MICE. Drug Metabolism and Disposition, 2005, 33, 820-828.	3.3	73
24	Chemotherapy Dosing Schedule Influences Drug Resistance Development in Ovarian Cancer. Molecular Cancer Therapeutics, 2011, 10, 1289-1299.	4.1	68
25	In vitro andin vivo evaluation of WK-X-34, a novel inhibitor of P-glycoprotein and BCRP, using radio imaging techniques. International Journal of Cancer, 2006, 119, 414-422.	5.1	67
26	Effect of Chronic Kidney Disease on Nonrenal Elimination Pathways: A Systematic Assessment of CYP1A2, CYP2C8, CYP2C9, CYP2C19, and OATP. Clinical Pharmacology and Therapeutics, 2018, 103, 854-867.	4.7	65
27	Impact of Polyinosinic/Polycytidylic Acid on Placental and Hepatobiliary Drug Transporters in Pregnant Rats. Drug Metabolism and Disposition, 2010, 38, 1760-1766.	3.3	64
28	Inflammation and Interleukin-6 Mediate Reductions in the Hepatic Expression and Transcription of the mdr1a and mdr1b Genes. Molecular Cell Biology Research Communications: MCBRC: Part B of Biochemical and Biophysical Research Communications, 2000, 4, 248-256.	1.6	63
29	In vitro and in vivo characterization of a novel biocompatible polymerâ€“lipid implant system for the sustained delivery of paclitaxel. Journal of Controlled Release, 2005, 104, 181-191.	9.9	63
30	Novel biocompatible intraperitoneal drug delivery system increases tolerability and therapeutic efficacy of paclitaxel in a human ovarian cancer xenograft model. Cancer Chemotherapy and Pharmacology, 2007, 60, 907-914.	2.3	63
31	Drug release mechanism of paclitaxel from a chitosanâ€“lipid implant system: Effect of swelling, degradation and morphology. European Journal of Pharmaceutics and Biopharmaceutics, 2008, 69, 149-157.	4.3	63
32	Drug transport across the placenta, role of the ABC drug efflux transporters. Expert Opinion on Drug Metabolism and Toxicology, 2007, 3, 819-830.	3.3	62
33	Aprepitant and fosaprepitant drug interactions: a systematic review. British Journal of Clinical Pharmacology, 2017, 83, 2148-2162.	2.4	62
34	Selective effect of adjuvant arthritis on the disposition of propranolol enantiomers in rats detected using a stereospecific HPLC assay. Pharmaceutical Research, 1993, 10, 294-299.	3.5	61
35	Cytokines Alter the Expression and Activity of the Multidrug Resistance Transporters in Human Hepatoma Cell Lines; Analysis Using RTâ€PCR and cDNA Microarrays. Journal of Pharmaceutical Sciences, 2003, 92, 2152-2163.	3.3	61
36	Effects of sustained and intermittent paclitaxel therapy on tumor repopulation in ovarian cancer. Molecular Cancer Therapeutics, 2008, 7, 630-637.	4.1	61

#	Article	IF	Citations
37	Impact of intraperitoneal, sustained delivery of paclitaxel on the expression of P-glycoprotein in ovarian tumors. Journal of Controlled Release, 2007, 117, 20-27.	9.9	57
38	Regulation of Transporters by Nuclear Hormone Receptors: Implications during Inflammation. Molecular Pharmaceutics, 2008, 5, 67-76.	4.6	57
39	Effect of Endotoxin on the Expression of Placental Drug Transporters and Glyburide Disposition in Pregnant Rats. Drug Metabolism and Disposition, 2008, 36, 1944-1950.	3.3	53
40	Breast Cancer Resistance Protein (BCRP)-Mediated Glyburide Transport: Effect of the C421A/Q141K BCRP Single-Nucleotide Polymorphism. Drug Metabolism and Disposition, 2010, 38, 740-744.	3.3	51
41	Neurobiological Mechanisms of Chemotherapy-induced Cognitive Impairment in a Transgenic Model of Breast Cancer. Neuroscience, 2018, 369, 51-65.	2.3	51
42	Detection of P-glycoprotein activity in endotoxemic rats by 99mTc-sestamibi imaging. Journal of Nuclear Medicine, 2005, 46, 1537-45.	5.0	49
43	THE ROLE OF PREGNANE X RECEPTOR IN 2-ACETYLAMINOFLUORENE-MEDIATED INDUCTION OF DRUG TRANSPORT AND -METABOLIZING ENZYMES IN MICE. Drug Metabolism and Disposition, 2006, 34, 405-409.	3.3	47
44	Combination Drug Delivery Strategy for the Treatment of Multidrug Resistant Ovarian Cancer. Molecular Pharmaceutics, 2011, 8, 260-269.	4.6	46
45	Pharmacokinetic Studies in Pregnant Women. Clinical Pharmacology and Therapeutics, 2008, 83, 184-187.	4.7	43
46	Endotoxin Downregulates Hepatic Expression of P-Glycoprotein and MRP2 in 2-Acetylaminofluorene-Treated Rats. Molecular Cell Biology Research Communications: MCBRC: Part B of Biochemical and Biophysical Research Communications, 2000, 4, 90-97.	1.6	41
47	Expression of ABC Efflux Transporters in Placenta from Women with Insulin-Managed Diabetes. PLoS ONE, 2012, 7, e35027.	2.5	41
48	Recent advances in drug delivery strategies for treatment of ovarian cancer. Expert Opinion on Drug Delivery, 2012, 9, 567-583.	5.0	39
49	Comparison of the accumulation and efflux kinetics of technetium-99m sestamibi and technetium-99m tetrofosmin in an MRP-expressing tumour cell line. European Journal of Nuclear Medicine and Molecular Imaging, 2000, 27, 1786-1792.	2.1	38
50	Maternal bacterial infections impact expression of drug transporters in human placenta. International Immunopharmacology, 2015, 26, 349-356.	3.8	38
51	User considerations in assessing pharmacogenomic tests and their clinical support tools. Npj Genomic Medicine, 2018, 3, 26.	3.8	38
52	Continuous Docetaxel Chemotherapy Improves Therapeutic Efficacy in Murine Models of Ovarian Cancer. Molecular Cancer Therapeutics, 2010, 9, 1820-1830.	4.1	36
53	The impact of sustained and intermittent docetaxel chemotherapy regimens on cognition and neural morphology in healthy mice. Psychopharmacology, 2014, 231, 841-852.	3.1	35
54	Effects of lipopolysaccharide-stimulated inflammation and pyrazole-mediated hepatocellular injury on mouse hepatic Cyp2a5 expression. Toxicology, 2003, 184, 211-226.	4.2	34

#	Article	IF	Citations
55	Effect of a high-fat diet on the hepatic expression of nuclear receptors and their target genes: relevance to drug disposition. British Journal of Nutrition, 2015, 113, 507-516.	2.3	34
56	Chitosanâ€“phospholipid blend for sustained and localized delivery of docetaxel to the peritoneal cavity. International Journal of Pharmaceutics, 2009, 377, 76-84.	5.2	32
57	Bloodâ€“brain barrier: An impediment to neuropharmaceuticals. Clinical Pharmacology and Therapeutics, 2015, 97, 308-313.	4.7	32
58	PHARMACOKINETICS AND MULTIPLE PEAKING OF ACEBUTOLOL ENANTIOMERS IN RATS. , 1997, 18, 543-556.		29
59	An injectable depot system for sustained intraperitoneal chemotherapy of ovarian cancer results in favorable drug distribution at the whole body, peritoneal and intratumoral levels. Journal of Controlled Release, 2012, 158, 379-385.	9.9	29
60	Pharmacokinetics of Acebutolol Enantiomers in Humans. Journal of Pharmaceutical Sciences, 1991, 80, 313-316.	3.3	27
61	A Continuing Professional Development Program for Pharmacists Implementing Pharmacogenomics into Practice. Pharmacy (Basel, Switzerland), 2020, 8, 55.	1.6	26
62	Regulation of Drug Transport Proteinsâ€”From Mechanisms to Clinical Impact: A White Paper on Behalf of the International Transporter Consortium. Clinical Pharmacology and Therapeutics, 2022, 112, 461-484.	4.7	26
63	Impact of Hyperlipidemia on Plasma Protein Binding and Hepatic Drug Transporter and Metabolic Enzyme Regulation in a Rat Model of Gestational Diabetes. Journal of Pharmacology and Experimental Therapeutics, 2010, 334, 21-32.	2.5	25
64	Ratio-Dependent Synergism of a Doxorubicin and Olaparib Combination in 2D and Spheroid Models of Ovarian Cancer. Molecular Pharmaceutics, 2018, 15, 472-485.	4.6	24
65	Novel tetrahydroisoquinolin-ethyl-phenylamine based multidrug resistance inhibitors with broad-spectrum modulating properties. Cancer Chemotherapy and Pharmacology, 2006, 59, 61-69.	2.3	23
66	Poly(I:C) alters placental and fetal brain amino acid transport in a rat model of maternal immune activation. American Journal of Reproductive Immunology, 2019, 81, e13115.	1.2	23
67	Impact of Acute Streptozotocinâ€Induced Diabetes on ABC Transporter Expression in Rats. Chemistry and Biodiversity, 2009, 6, 1943-1959.	2.1	22
68	Involvement of Nuclear Factor Î²B, not Pregnane X Receptor, in Inflammation-Mediated Regulation of Hepatic Transporters. Drug Metabolism and Disposition, 2017, 45, 1077-1083.	3.3	20
69	Influence of molecular organization and interactions on drug release for an injectable polymer-lipid blend. International Journal of Pharmaceutics, 2008, 360, 83-90.	5.2	19
70	Malaria Infection Alters the Expression of Hepatobiliary and Placental Drug Transporters in Pregnant Mice. Drug Metabolism and Disposition, 2014, 42, 603-610.	3.3	19
71	Gestational and Pregnane X Receptor-Mediated Regulation of Placental ATP-Binding Cassette Drug Transporters in Mice. Drug Metabolism and Disposition, 2011, 39, 465-471.	3.3	18
72	Effect of Aging on the Pharmacokinetics of Acebutolol Enantiomers. Journal of Clinical Pharmacology, 1992, 32, 148-156.	2.0	17

#	Article	IF	Citations
73	Characterization of guanidine transport in human renal brush border membranes. Pharmaceutical Research, 1997, 14, 936-941.	3.5	16
74	Mechanisms of Reduced Maternal and Fetal Lopinavir Exposure in a Rat Model of Gestational Diabetes. Drug Metabolism and Disposition, 2011, 39, 1850-1859.	3.3	14
75	Synthesis and Physicochemical and Dynamic Mechanical Properties of a Water-Soluble Chitosan Derivative as a Biomaterial. Biomacromolecules, 2006, 7, 3548-3548.	5.4	13
76	99mTc-Sestamibi, A Sensitive Probe for In Vivo Imaging of P-Glycoprotein Inhibition by Modulators and mdr1 Antisense Oligodeoxynucleotides. Molecular Imaging and Biology, 2006, 8, 333-339.	2.6	12
77	KLF6 and HSF4 transcriptionally regulate multidrug resistance transporters during inflammation. Biochemical and Biophysical Research Communications, 2007, 353, 679-685.	2.1	12
78	Docetaxel Distribution Following Intraperitoneal Administration in Mice. Journal of Pharmacy and Pharmaceutical Sciences, 2011, 14, 90.	2.1	12
79	Polyinosinic/Polycytidylic Acidâ€“Mediated Changes in Maternal and Fetal Disposition of Lopinavir in Rats. Drug Metabolism and Disposition, 2015, 43, 951-957.	3.3	12
80	BRCA Status Does Not Predict Synergism of a Carboplatin and Olaparib Combination in High-Grade Serous Ovarian Cancer Cell Lines. Molecular Pharmaceutics, 2018, 15, 2742-2753.	4.6	12
81	Epigenetics: A New Link Toward Understanding Human Disease and Drug Response. Clinical Pharmacology and Therapeutics, 2012, 92, 669-673.	4.7	11
82	Impact of Viral Inflammation on the Expression of Renal Drug Transporters in Pregnant Rats. Pharmaceutics, 2019, 11, 624.	4.5	11
83	Role of Elevated SFLTâ€1 on the Regulation of Placental Transporters in Women With Preâ€Eclampsia. Clinical and Translational Science, 2020, 13, 580-588.	3.1	11
84	Network Medicine: Finding the Links to Personalized Therapy. Clinical Pharmacology and Therapeutics, 2013, 94, 613-616.	4.7	10
85	The Effects of Lipiodol and Cyclosporin A on the Hepatobiliary Disposition of Doxorubicin in Pigs. Molecular Pharmaceutics, 2014, 11, 1301-1313.	4.6	9
86	Endotoxin-Mediated Downregulation of Hepatic Drug Transporters in HIV-1 Transgenic Rats. Drug Metabolism and Disposition, 2016, 44, 709-719.	3.3	9
87	STAT3 is involved in IL-6-Mediated Downregulation of Hepatic Transporters in Mice. Journal of Pharmacy and Pharmaceutical Sciences, 2018, 21, 325s-334s.	2.1	9
88	Role of HIV and Antiretroviral Therapy on the Expression of Placental Transporters in Women with HIV. AAPS Journal, 2020, 22, 138.	4.4	9
89	Functional comparison of single- and double-stranded mdr1 antisense oligodeoxynucleotides in human ovarian cancer cell lines. Journal of Pharmacy and Pharmaceutical Sciences, 2005, 8, 516-27.	2.1	9
90	Transporter Regulation in Critical Protective Barriers: Focus on Brain and Placenta. Pharmaceutics, 2022, 14, 1376.	4.5	9

#	Article	IF	Citations
91	Translational Pharmacology: Harnessing Increased Specialization of Research Within the Basic Biological Sciences. Clinical Pharmacology and Therapeutics, 2008, 83, 797-801.	4.7	8
92	Pharmacogenetics of Pharmacoecology: Which Route to Personalized Medicine?. Clinical Pharmacology and Therapeutics, 2009, 85, 343-348.	4.7	8
93	Continuous Intraperitoneal Carboplatin Delivery for the Treatment of Late-Stage Ovarian Cancer. Molecular Pharmaceutics, 2013, 10, 3315-3322.	4.6	8
94	Inflammation: The Dynamic Force of Health and Disease. Clinical Pharmacology and Therapeutics, 2014, 96, 401-405.	4.7	8
95	Impact of endotoxin on the expression of drug transporters in the placenta of HIV-1 transgenic (HIV-Tg) rats. European Journal of Pharmaceutical Sciences, 2017, 102, 94-102.	4.0	8
96	Essential role of STAT-3 dependent NF-Îºß activation on IL-6-mediated downregulation of hepatic transporters. European Journal of Pharmaceutical Sciences, 2020, 143, 105151.	4.0	8
97	Pharmacists as Personalized Medicine Experts (PRIME): Experiences Implementing Pharmacist-Led Pharmacogenomic Testing in Primary Care Practices. Pharmacy (Basel, Switzerland), 2021, 9, 201.	1.6	8
98	Endotoxin Modulates the Expression of Renal Drug Transporters in HIV-1 Transgenic Rats. Journal of Pharmacy and Pharmaceutical Sciences, 2018, 21, 117s-129s.	2.1	7
99	The Age of Omicsâ€Driven Precision Medicine. Clinical Pharmacology and Therapeutics, 2019, 106, 477-481.	4.7	7
100	Viral model of maternal immune activation alters placental AMPK and mTORC1 signaling in rats. Placenta, 2021, 112, 36-44.	1.5	7
101	SLC Neurotransmitter Transporters as Therapeutic Targets for Alcohol Use Disorder: A Narrative Review. Alcoholism: Clinical and Experimental Research, 2020, 44, 1965-1976.	2.4	6
102	Potential Limitations of Bioluminescent Xenograft Mouse Models: A Systematic Review. Journal of Pharmacy and Pharmaceutical Sciences, 2020, 23, 177-199.	2.1	6
103	Impact of Th-17 Cytokines on the Regulation of Transporters in Human Placental Explants. Pharmaceutics, 2021, 13, 881.	4.5	6
104	PREGNANCY OUTCOMES AFTER EXPOSURE TO TNF-Î± INHIBITORS FOR THE TREATMENT OF ARTHRITIC DISEASES: A META-ANALYSIS OF OBSERVATIONAL STUDIES. Canadian Journal of Clinical Pharmacology, 2018, 25, e53-e56.	1.1	6
105	Optimizing Cancer Care: Is the Future Bright?. Clinical Pharmacology and Therapeutics, 2011, 90, 347-350.	4.7	5
106	Dysregulation of solute carrier transporters in malariaâ€infected pregnant mice. Parasite Immunology, 2019, 41, e12614.	1.5	5
107	Impact of Inflammation and Infection on the Expression of Amino Acid Transporters in the Placenta: A Minireview. Drug Metabolism and Disposition, 2022, 50, 1251-1258.	3.3	5
108	Pharmacokinetics in pregnancy. , 2011, , 39-45.		4

#	Article	IF	Citations
109	The Role of PXR Genotype and Transporter Expression in the Placental Transport of Lopinavir in Mice. Pharmaceutics, 2017, 9, 49.	4.5	4
110	Expression of Human Polyspecific Renal Organic Cation Transport Activity in Xenopus laevis Oocytes. Journal of Pharmaceutical Sciences, 1997, 86, 753-755.	3.3	3
111	Dysregulation of renal transporters in a rodent model of viral Infection. International Immunopharmacology, 2020, 80, 106135.	3.8	3
112	The Bugs Within Our Body: The Human Microbiota. Clinical Pharmacology and Therapeutics, 2016, 99, 570-574.	4.7	2
113	Battling the <scp>HIV</scp>/<scp>AIDS</scp> Epidemic: Triumphs and Barriers. Clinical Pharmacology and Therapeutics, 2018, 104, 1042-1046.	4.7	2
114	Development of a Bioluminescent BRCA1-Deficient Xenograft Model of Disseminated, High-Grade Serous Ovarian Cancer. International Journal of Molecular Sciences, 2019, 20, 2498.	4.1	2
115	PHARMACOKINETICS AND MULTIPLE PEAKING OF ACEBUTOLOL ENANTIOMERS IN RATS. Biopharmaceutics and Drug Disposition, 1997, 18, 543-556.	1.9	2
116	Response to â€˜Aprepitant and fosaprepitant decrease the effectiveness of hormonal contraceptivesâ€™. British Journal of Clinical Pharmacology, 2018, 84, 604-604.	2.4	1
117	Pharmacokinetics in pregnancy. , 2022, , 33-46.		1
118	In vivo disposition and stability of DNA frayed wires in mice. International Journal of Biological Macromolecules, 2006, 39, 310-316.	7.5	0
119	Novel drug-delivery strategies for the treatment of ovarian cancer. Expert Review of Obstetrics and Gynecology, 2007, 2, 587-593.	0.4	0
120	Within Our Skin. Clinical Pharmacology and Therapeutics, 2017, 102, 8-12.	4.7	0
121	Pharmacokinetics in Pregnancy. , 2017, , 39-49.		0
122	Drug Transporters: Efflux. , 2021, , .		0
123	p53 and Multidrug Resistance Transporters in the Central Nervous System. , 2006, , 373-388.		0
124	Downregulation of BCRP (ABCG2) in Placenta of Rat Model of Preeclampsia. FASEB Journal, 2022, 36, .	0.5	0